HUE042607T2 - Eljárások asztma exacerbációs gyakoriságának csökkentésére benralizumab alkalmazásával - Google Patents

Eljárások asztma exacerbációs gyakoriságának csökkentésére benralizumab alkalmazásával

Info

Publication number
HUE042607T2
HUE042607T2 HUE14835826A HUE14835826A HUE042607T2 HU E042607 T2 HUE042607 T2 HU E042607T2 HU E14835826 A HUE14835826 A HU E14835826A HU E14835826 A HUE14835826 A HU E14835826A HU E042607 T2 HUE042607 T2 HU E042607T2
Authority
HU
Hungary
Prior art keywords
benralizumab
exacerbation
asthma
frequency
reducing
Prior art date
Application number
HUE14835826A
Other languages
English (en)
Hungarian (hu)
Inventor
Christine Ward
Lorin Roskos
Bing Wang
Donald Raible
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HUE042607T2 publication Critical patent/HUE042607T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Bathtubs, Showers, And Their Attachments (AREA)
HUE14835826A 2013-08-12 2014-08-07 Eljárások asztma exacerbációs gyakoriságának csökkentésére benralizumab alkalmazásával HUE042607T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361864944P 2013-08-12 2013-08-12

Publications (1)

Publication Number Publication Date
HUE042607T2 true HUE042607T2 (hu) 2019-07-29

Family

ID=52448837

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14835826A HUE042607T2 (hu) 2013-08-12 2014-08-07 Eljárások asztma exacerbációs gyakoriságának csökkentésére benralizumab alkalmazásával

Country Status (26)

Country Link
US (2) US9441037B2 (https=)
EP (1) EP3033101B1 (https=)
JP (4) JP6746495B2 (https=)
KR (2) KR20220057637A (https=)
CN (2) CN105451760A (https=)
AU (2) AU2014306956B2 (https=)
BR (1) BR112016002401A8 (https=)
CA (1) CA2918105C (https=)
CY (1) CY1122132T1 (https=)
DK (1) DK3033101T3 (https=)
ES (1) ES2716906T3 (https=)
HK (1) HK1221644A1 (https=)
HR (1) HRP20190405T1 (https=)
HU (1) HUE042607T2 (https=)
LT (1) LT3033101T (https=)
ME (1) ME03348B (https=)
MX (1) MX368508B (https=)
PL (1) PL3033101T3 (https=)
PT (1) PT3033101T (https=)
RS (1) RS58404B1 (https=)
RU (1) RU2676333C2 (https=)
SG (2) SG10202005560UA (https=)
SI (1) SI3033101T1 (https=)
SM (1) SMT201900163T1 (https=)
TR (1) TR201903312T4 (https=)
WO (1) WO2015023504A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100152T1 (it) 2013-08-12 2021-05-07 Astrazeneca Ab Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab
RU2728578C2 (ru) * 2013-08-12 2020-07-30 Астразенека Аб Способы нормализации симптомов астмы с применением бенрализумаба
WO2015057668A1 (en) * 2013-10-15 2015-04-23 Medimmune, Llc Methods for treating chronic obstructive pulmonary disease using benralizumab
CA2926089C (en) * 2013-10-24 2022-08-30 Medimmune, Llc Stable, aqueous antibody formulations
ES2866935T3 (es) 2014-01-10 2021-10-20 Anaptysbio Inc Anticuerpos dirigidos contra interleucina-33 (IL-33)
US10846696B2 (en) 2015-08-24 2020-11-24 Samsung Electronics Co., Ltd. Apparatus and method for trusted execution environment based secure payment transactions
US10699274B2 (en) 2015-08-24 2020-06-30 Samsung Electronics Co., Ltd. Apparatus and method for secure electronic payment
EP3371225A2 (en) 2015-11-04 2018-09-12 AstraZeneca AB Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
EP3565823B1 (en) 2017-01-04 2024-05-29 Worg Pharmaceuticals (Zhejiang) Co., Ltd. S-arrestin peptides and therapeutic uses thereof
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005035583A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Il-5受容体に特異的に結合する抗体組成物
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
MX376656B (es) 2007-05-14 2025-03-07 Kyowa Kirin Co Ltd Metodos para reducir niveles de basófilos.
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
AU2010322066A1 (en) * 2009-11-18 2012-06-21 Medicinova, Inc. Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom
RU2578468C2 (ru) 2010-12-16 2016-03-27 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием th2
WO2012158954A1 (en) 2011-05-18 2012-11-22 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
US20140328839A1 (en) 2011-11-01 2014-11-06 Medlmmune, Llc Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma
RU2728578C2 (ru) 2013-08-12 2020-07-30 Астразенека Аб Способы нормализации симптомов астмы с применением бенрализумаба
SMT202100152T1 (it) 2013-08-12 2021-05-07 Astrazeneca Ab Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab

Also Published As

Publication number Publication date
EP3033101A4 (en) 2017-07-12
AU2014306956B2 (en) 2019-11-21
MX368508B (es) 2019-10-07
JP2022120009A (ja) 2022-08-17
PT3033101T (pt) 2019-04-02
ES2716906T3 (es) 2019-06-17
DK3033101T3 (en) 2019-04-08
BR112016002401A8 (pt) 2018-06-12
RU2016108723A (ru) 2017-09-19
HK1225302B (en) 2017-09-08
MX2016001383A (es) 2016-08-03
LT3033101T (lt) 2019-03-25
US20170198049A1 (en) 2017-07-13
KR102390714B1 (ko) 2022-04-26
JP2024129139A (ja) 2024-09-26
SI3033101T1 (sl) 2019-04-30
HRP20190405T1 (hr) 2019-04-19
BR112016002401A2 (pt) 2017-09-12
CN105451760A (zh) 2016-03-30
KR20220057637A (ko) 2022-05-09
SG10202005560UA (en) 2020-07-29
US20150044202A1 (en) 2015-02-12
RU2016108723A3 (https=) 2018-06-18
KR20160042121A (ko) 2016-04-18
WO2015023504A8 (en) 2015-09-24
HK1221644A1 (zh) 2017-06-09
CA2918105C (en) 2023-02-28
JP2020128375A (ja) 2020-08-27
CY1122132T1 (el) 2020-11-25
SG11201600481UA (en) 2016-02-26
PL3033101T3 (pl) 2019-06-28
SMT201900163T1 (it) 2019-05-10
JP6746495B2 (ja) 2020-08-26
RU2676333C2 (ru) 2018-12-28
AU2020201327A1 (en) 2020-03-12
TR201903312T4 (tr) 2019-04-22
EP3033101B1 (en) 2018-12-19
US9441037B2 (en) 2016-09-13
WO2015023504A1 (en) 2015-02-19
AU2014306956A1 (en) 2016-02-04
EP3033101A1 (en) 2016-06-22
ME03348B (me) 2019-10-20
CN111588848A (zh) 2020-08-28
RS58404B1 (sr) 2019-04-30
CA2918105A1 (en) 2015-02-19
JP2016527324A (ja) 2016-09-08

Similar Documents

Publication Publication Date Title
IL291446A (en) Anti-trop2 antibodies and methods for producing same
HUE042607T2 (hu) Eljárások asztma exacerbációs gyakoriságának csökkentésére benralizumab alkalmazásával
IL246002A0 (en) Novel methods
IL244422A0 (en) Anti-b7-h1 antibodies for treating tumors
LT3004166T (lt) Alergeno atžvilgiu specifinės imunoterapijos sustiprinimo būdai, įvedant il-4r inhibitorių
PT3305778T (pt) Inibidores de calicreína plasmática
PL3033336T3 (pl) Inhibitory kalikreiny w plaźmie
HUE057530T2 (hu) Integrált eljárás szénhidrogének elõállítására
HUE045051T2 (hu) Eljárás propilén-oxid elõállítására
LT3563837T (lt) Terapija bakteriofagu
HUE053751T2 (hu) Eljárás iopamidol elõállítására
GB201313771D0 (en) Acoustic liner
EP2963676A4 (en) susceptor
ZA201507475B (en) Method for the treatment of gas
SG10201708272SA (en) Method of Viral Inhibition
EP2875389A4 (en) ACOUSTIC ISOLATOR FOR DRILLING TOOLS
PT2799426T (pt) Novo processo para a síntese de aminaftona
PL2883461T3 (pl) Sposób wytwarzania aktywnej folistatyny
EP2943578A4 (en) Dnazyme for silencing the expression of egfr
GB201301125D0 (en) Methods for improving the efficency of gene targeting
SG11201602693QA (en) Methods and intermediates for preparing macrolactams
EP3025467A4 (en) DETERMINATION OF A SEQUENCE OF PILOT FREQUENCIES
DK3063370T3 (da) Frakturkaraterisering
PL3063156T3 (pl) Sposób oczyszczania lecytyny
GB201303254D0 (en) Cross braced tympanic guitar